Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Hemoglobinopathies

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with hemoglobinopathies. However, the applicability of HSCT has been limited mainly by donor availability, with only 25-30% of patients having human leukocyte antigen (HLA)-matched sibling donors. Previous outcomes using alternate donor options have been markedly inferior due to increased regimen related toxicity, transplant related mortality, graft failure and graft-versus-host disease (GVHD). Advances in transplant technology, including high resolution HLA typing, improved GVHD prophylactic approaches with tolerance induction, and better supportive care over the last decade, are addressing these historical challenges, resulting in increasing donor options.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research